Cargando…

Recombinant Human Parathyroid Hormone Related Protein 1-34 and 1-84 and Their Roles in Osteoporosis Treatment

Osteoporosis is a common disorder characterized by compromised bone strength that predisposes patients to increased fracture risk. Parathyroid hormone related protein (PTHrP) is one of the candidates for clinical osteoporosis treatment. In this study, GST Gene Fusion System was used to express recom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hua, Liu, Jingning, Yin, Ying, Wu, Jun, Wang, Zilu, Miao, Dengshun, Sun, Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916416/ https://www.ncbi.nlm.nih.gov/pubmed/24516619 http://dx.doi.org/10.1371/journal.pone.0088237

Ejemplares similares

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
por: Jódar-Gimeno, Esteban
Publicado: (2007)

Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
por: Deng, Jing, et al.
Publicado: (2018)

Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism
por: Watts, Nelson B, et al.
Publicado: (2023)

Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis
por: Pietrogrande, Luca
Publicado: (2010)

Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis
por: Pearson, Richard G., et al.
Publicado: (2019)

Effects of recombinant human parathyroid hormone (1-34) on cell proliferation, chemokine expression and the Hedgehog pathway in keratinocytes
por: Bu, Xiaolin, et al.
Publicado: (2018)

Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation
por: Osagie-Clouard, L., et al.
Publicado: (2017)

A Phase I Randomized Trial of Once‐Daily Versus Twice‐Daily Recombinant Human Parathyroid Hormone (1‐84) for Hypoparathyroidism
por: Ing, Steven W., et al.
Publicado: (2023)

OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
por: Bilezikian, John, et al.
Publicado: (2019)

Development and in vivo evaluation of intranasal formulations of parathyroid hormone (1-34)
por: Wang, Dan, et al.
Publicado: (2021)

Parathyroid Hormone Administration Improves Bone Marrow Microenvironment and Partially Rescues Haematopoietic Defects in Bmi1-Null Mice
por: Lu, Ruinan, et al.
Publicado: (2014)

Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
por: Petrova, Nina L., et al.
Publicado: (2021)

ClC-3 chloride channel mediates the role of parathyroid hormone [1-34] on osteogenic differentiation of osteoblasts
por: Lu, Xiaolin, et al.
Publicado: (2017)

Self-Dissolving Microneedle Arrays for Transdermal Absorption Enhancement of Human Parathyroid Hormone (1-34)
por: Naito, Chihiro, et al.
Publicado: (2018)

A Novel Approach for High Level Expression of Soluble Recombinant Human Parathyroid Hormone (rhPTH 1-34) in Escherichia coli
por: Hamedifar, Haleh, et al.
Publicado: (2013)

DNA damage checkpoint pathway modulates the regulation of skeletal growth and osteoblastic bone formation by parathyroid hormone-related peptide
por: Zhang, Ying, et al.
Publicado: (2018)

Effects of parathyroid hormone (1-34) on the regulation of the lysyl oxidase family in ovariectomized mice
por: Cai, Linyi, et al.
Publicado: (2018)

Optimal timing for intermittent administration of parathyroid hormone (1–34) for distraction osteogenesis in rabbits
por: Inada, Narisaku, et al.
Publicado: (2022)

Parathyroid hormone 1–34 inhibits senescence in rat nucleus pulposus cells by activating autophagy via the m-TOR pathway
por: Wang, Xiao-Ying, et al.
Publicado: (2018)

Effects of parathyroid hormone rhPTH(1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
por: Clarke, Bart L., et al.
Publicado: (2016)

The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of OSteoporosis (PaVOS)- study protocol for a randomized controlled trial
por: Jepsen, Ditte Beck, et al.
Publicado: (2018)

The combined effect of Parathyroid hormone (1–34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial
por: Jepsen, D. B., et al.
Publicado: (2019)

Safety and Efficacy of Oral Human Parathyroid Hormone (1‐34) in Hypoparathyroidism: An Open‐Label Study
por: Ish‐Shalom, Sofia, et al.
Publicado: (2021)

Exogenous Parathyroid Hormone Alleviates Intervertebral Disc Degeneration through the Sonic Hedgehog Signalling Pathway Mediated by CREB
por: Li, You, et al.
Publicado: (2022)

Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation
por: Kimura, Shigemi, et al.
Publicado: (2014)

Attenuation of Alzheimer’s brain pathology in 5XFAD mice by PTH(1-34), a peptide of parathyroid hormone
por: Chen, Li, et al.
Publicado: (2023)

The Calcium-Sensing Receptor Mediates Bone Turnover Induced by Dietary Calcium and Parathyroid Hormone in Neonates
por: Shu, Lei, et al.
Publicado: (2011)

The association between parathyroid hormone 1–34 and the Wnt/β-catenin signaling pathway in a rat model of osteoarthritis
por: Ma, Long, et al.
Publicado: (2017)

Parathyroid hormone (1-34) ameliorates cartilage degeneration and subchondral bone deterioration in collagenase-induced osteoarthritis model in mice
por: Shao, Li-tao, et al.
Publicado: (2020)

Synergistic effects of high dietary calcium and exogenous parathyroid hormone in promoting osteoblastic bone formation in mice
por: Feng, Yuxu, et al.
Publicado: (2015)

The Parathyroid Hormone-Related Protein/Parathyroid Hormone 1 Receptor Axis in Adipose Tissue
por: Izquierdo-Lahuerta, Adriana
Publicado: (2021)

Parathyroid Hormone-Related Protein/Parathyroid Hormone Receptor 1 Signaling in Cancer and Metastasis
por: Zhao, Yawei, et al.
Publicado: (2023)

Parathyroid Hormone 1-34(Teriparatide) Treatment in Pelvic Insufficiency Fractures - A Report of Two Cases -
por: Moon, Sang-Won, et al.
Publicado: (2012)

Intermittently Administered Parathyroid Hormone [1–34] Promotes Tendon-Bone Healing in a Rat Model
por: Bi, Fanggang, et al.
Publicado: (2014)

Single and Combined use of Human Parathyroid Hormone (PTH) (1-34) on Areal Bone Mineral Density (aBMD) in Postmenopausal Women with Osteoporosis: Evidence Based on 9 RCTs
por: Song, Jiefu, et al.
Publicado: (2014)

Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia
por: Braverman, Eric R, et al.
Publicado: (2009)

The Transcription Factor Foxc1 Promotes Osteogenesis by Directly Regulating Runx2 in Response of Intermittent Parathyroid Hormone (1–34) Treatment
por: Ouyang, Ningjuan, et al.
Publicado: (2020)

Intermittent Administration of Parathyroid Hormone [1–34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model
por: Bi, Fanggang, et al.
Publicado: (2015)

Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
por: Hwang, Seung Rim, et al.
Publicado: (2016)

Triweekly administration of parathyroid hormone (1–34) accelerates bone healing in a rat refractory fracture model
por: Kumabe, Yohei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rt0hf5vb5ikbbcl6u06g94pfid